UNCY שווי כולל של נכסי החברה Unicycive Therapeutics Inc.

Unicycive Therapeutics (UNCY) is developing advanced molecules to combat hyperphosphatemia while awaiting the results of Renazorb's Phase 3 trials. The business relies on reducing phosphate levels in dialysis patients, establishing a defensive barrier within the nephrology sector. The price action on the total assets chart is currently fixed at 51.01. Unicycive Therapeutics aims for expansion through the implementation of Oxylanthanum Carbonate following FDA approval to capture market share.

By leveraging production outsourcing through CDMOs, Unicycive Therapeutics minimizes capital expenditures, which reflects the current level of 51.01 in the analysis of total balance sheet assets. A reverse calculation via ROA allows for tracking the dynamics of the resource base; meanwhile, any local decline in this indicator signals a transformation of the fundamental basis, increasing the risk of a decline in business value.